-
Pharma Congress 2025: Enforcement actions, EOs and guidance docs
Conference speakers drew attention to cases and guidance documents showcasing the Trump administration’s enforcement and policy priorities.
-
Pharma Congress 2025: Monitoring off-label use
Panelists emphasized that the healthcare programs your organization wants to offer will get better results when closely monitored and constantly improved.
-
DOJ signals hard line on duty evasion as tariff regime firms up
Settlement of $12.4m under False Claims Act shows tariff evasion will be pursued as fraud.
-
Attempt to game Lifeline program results in $110m fine
Q Link Wireless will pay $110.6m after admitting to a scheme that bilked the FCC’s Lifeline Program by billing for phantom customers and fabricating phone usage records.
-
DOJ charges 324 defendants in largest healthcare fraud initiative in its history
The collaborative Takedown effort targeted healthcare fraud that victimizes patients, taxpayers and government programs.
-
DOJ and HHS announce False Claims Act Working Group
Collaboration aims to advance both departments’ priority enforcement areas by sharing resources in pursuing False Claims Act violations.
-
CVS Caremark’s $95m penalty for Medicare drug overbilling
Whistleblower alleged Caremark reported higher costs of drugs to the government than it paid pharmacies for dispensing Medicare Part D drugs.
-
Trump administration uses False Claims Act to pursue anti-DEI goals
An investigation into Harvard’s admissions policies and a DOJ memo demonstrate how the False Claims Act could be deployed to crack down on DEI.